Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00520169 · ClinicalTrials.gov registry record · Phase 1
Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine
A Phase 1 study, sponsored by Javelin Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00520169 is a Phase 1 study that has completed, run by Javelin Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT00520169, a Phase 1 study, has completed, sponsored by Javelin Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is an open label, single-center study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers.
Interventions
- DRUG intranasal ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2007-07 |
| Est. Completion | 2007-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00520169
The ClinicalTrials.gov registry entry for NCT00520169 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Javelin Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which intranasal ketamine is the first listed.
NCT00520169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00520169 about?
NCT00520169 is a clinical study titled "Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine". This is an open label, single-center study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers.
What is the current status of trial NCT00520169?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2007-07. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00520169?
The interventions under investigation include: intranasal ketamine (DRUG).
Who is sponsoring clinical trial NCT00520169?
This trial is sponsored by Javelin Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.